Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaohui Zeng

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Clinical Drug Investigation|November 4, 2019
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness AnalysisQiao Liu, Xia Luo, Liubao Peng, et al.
Experimental and Therapeutic Medicine|June 20, 2014
Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat dietYaosheng Tu, Dongmei Sun, Xiaohui Zeng, et al.
Scientific Reports|November 29, 2022
Propagation characteristics and prediction of airblast overpressure outside tunnel: a case studyXianshun Zhou, Xuemin Zhang, Lichuan Wang, et al.
European Journal of Pharmacology|October 11, 2017
Prevention of cholesterol gallstone disease by schaftoside in lithogenic diet-induced C57BL/6 mouse modelMeijing Liu, Changhui Liu, Hao Chen, et al.
Frontiers in Pharmacology|September 12, 2022
Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in ChinaDongchu Zhou, Xia Luo, Zhen Zhou, et al.
Food & Function|July 23, 2011
Protective actions of microalgae against endogenous and exogenous advanced glycation endproducts (AGEs) in human retinal pigment epithelial cellsZheng Sun, Jin Liu, Xiaohui Zeng, et al.
Clinical Drug Investigation|June 29, 2019
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in ChinaJun Chen, Gaoyun Hu, Zhuo Chen, et al.
BMJ Open|December 14, 2019
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USAXiaohui Zeng, Xiaomin Wan, Liubao Peng, et al.
Advances in Therapy|October 3, 2019
Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in ChinaYe Peng, Fang Ma, Chongqing Tan, et al.
Respiratory Research|May 24, 2019
Potential role of sympathetic activity on the pathogenesis of massive pulmonary embolism with circulatory shock in rabbitsYuting Wang, Delong Yu, Yijun Yu, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Clinical Drug Investigation|November 4, 2019
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness AnalysisQiao Liu, Xia Luo, Liubao Peng, et al.
Experimental and Therapeutic Medicine|June 20, 2014
Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat dietYaosheng Tu, Dongmei Sun, Xiaohui Zeng, et al.
Scientific Reports|November 29, 2022
Propagation characteristics and prediction of airblast overpressure outside tunnel: a case studyXianshun Zhou, Xuemin Zhang, Lichuan Wang, et al.
European Journal of Pharmacology|October 11, 2017
Prevention of cholesterol gallstone disease by schaftoside in lithogenic diet-induced C57BL/6 mouse modelMeijing Liu, Changhui Liu, Hao Chen, et al.
Frontiers in Pharmacology|September 12, 2022
Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in ChinaDongchu Zhou, Xia Luo, Zhen Zhou, et al.
Food & Function|July 23, 2011
Protective actions of microalgae against endogenous and exogenous advanced glycation endproducts (AGEs) in human retinal pigment epithelial cellsZheng Sun, Jin Liu, Xiaohui Zeng, et al.
Clinical Drug Investigation|June 29, 2019
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in ChinaJun Chen, Gaoyun Hu, Zhuo Chen, et al.
BMJ Open|December 14, 2019
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USAXiaohui Zeng, Xiaomin Wan, Liubao Peng, et al.
Advances in Therapy|October 3, 2019
Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in ChinaYe Peng, Fang Ma, Chongqing Tan, et al.
Respiratory Research|May 24, 2019
Potential role of sympathetic activity on the pathogenesis of massive pulmonary embolism with circulatory shock in rabbitsYuting Wang, Delong Yu, Yijun Yu, et al.
Pageof 13